Provided are a natural killer cell exhibiting increased anticancer activity and immunotherapeutic use thereof. According to the natural killer cell according to an aspect, a relative mean fluorescence intensity (MFI) of a specific receptor significant for cancers including glioblastoma is increased, and thus effective anticancer immunotherapy is possible.

Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

A chimeric antigen receptor containing a CLDN18.2 single domain antibody and an application thereof. The constructed chimeric antigen receptor is good in specificity, higher in safety in vivo use, and smaller in toxicity, and can provide a treatment solution for patients who suffer from advanced gastric cancer caused by high expression of a CLDN18.2 protein and currently undergo radiotherapy, chemotherapy, and surgery treatments.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic. In certain instances the immunotherapeutic is a chimeric antigen receptor T cell, an antibody or polypeptide that binds a checkpoint inhibitor, or a vaccine.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

The disclosure relates to a method of treating gastroesophageal cancer, and to a population of modified T cells expressing a heterologous TCR for use in such method.